Kymera Therapeutics, Inc. (KYMR) Stock
KYMR has an Alpha Score of 58 out of 100 (moderate), computed on Nov 6, 2026 from 2 of 4 sub-scores. 4 of the hedge funds AlphaScala tracks reported KYMR in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $19.21M. Company insiders reported 0 open-market buys and 9 sales on SEC Form 4 in the 90 days to Nov 9, 2026.
What is KYMR's Alpha Score?
How it works →Alpha Score of 58 reflects moderate overall profile with strong momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own KYMR?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 168K | $19.21M | NEW |
| Citadel Ken Griffin | 112K | $12.79M | -6% |
| Blackstone | 5K | $583.3K | -24% |
| D.E. Shaw David Shaw | 3K | $321.1K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Kymera Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Mainolfi Nello | Chief Executive Officer | SELL | 3.5K | $393K |
| Oct 1, 26 | Mainolfi Nello | Chief Executive Officer | SELL | 5.5K | $619K |
| Oct 1, 26 | Mainolfi Nello | Chief Executive Officer | SELL | 4.9K | $552K |
| Oct 1, 26 | Mainolfi Nello | Chief Executive Officer | SELL | 7.6K | $870K |
| Oct 1, 26 | Mainolfi Nello | Chief Executive Officer | SELL | 8.2K | $950K |
| Oct 1, 26 | Mainolfi Nello | Chief Executive Officer | SELL | 262 | $30K |
| Sep 4, 26 | Adams Brian | Chief Legal Officer | SELL | 1.2K | $140K |
| Sep 4, 26 | Adams Brian | Chief Legal Officer | SELL | 3.0K | $353K |
| Sep 4, 26 | Adams Brian | Chief Legal Officer | SELL | 2.1K | $251K |
SEC Form 4 filings as of Nov 9, 2026
See cluster-buy signals across all tickers →What are KYMR's key statistics?
Key statistics as of Oct 30, 2026
How does KYMR's valuation compare with the Healthcare sector?
| Metric | KYMR | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -285.34% | 3.62% | 174 |
| Return on equity | -21.50% | 2.96% | 200 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 10, 2026). P/E excludes loss-making companies.
KYMR price chart
Powered by TradingViewWhat does Kymera Therapeutics, Inc. do?
Kymera Therapeutics Inc. is a pioneering biotechnology company focused on the development of targeted protein degradation therapies. These therapies are aimed at disease-causing proteins that have traditionally been considered "undruggable." Kymera's primary function is to leverage its proprietary drug discovery platform to design small molecules that harness the cell's natural protein degradation processes, redirecting them to undesirable proteins and proteins involved in various diseases like cancer and immune-inflammatory conditions. This innovative approach holds significant promise for treating a multitude of diseases where conventional drug modalities are ineffective. Notably, Kymera's work impacts the healthcare and pharmaceutical industries by introducing novel therapeutic options and broadening the horizon for drug discovery and development. In the context of the financial market, Kymera Therapeutics represents a key player amid the emerging biotechnology companies that focus on cutting-edge science to address unmet medical needs. As such, it has captured the interest of stakeholders within both the investment community and the healthcare sector, highlighting its potential role in revolutionizing treatment paradigms on a global scale.